SCHEMBL311120

SCHEMBL311120

COCCOCCOCCOC(C)C

nearest known ligand 0.41

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
CA2 P00918 1/20 0.34
PIK3CD O00329 1/20 0.31
ALDH1A1 P00352 1/20 0.31
EPHX2 P34913 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10929539 1.00 CA2 (0.34) CA2PIK3CDALDH1A1EPHX2
SCHEMBL20175910 1.00 CA2 (0.34) CA2PIK3CDALDH1A1EPHX2
SCHEMBL811322 1.00 CA2 (0.34) CA2PIK3CDALDH1A1EPHX2
SCHEMBL47033 0.91
SCHEMBL28164439 0.91 PIK3CD (0.35) PIK3CDALDH1A1
SCHEMBL5024988 0.89 MEN1 (0.48) ALDH1A1EPHX2
SCHEMBL987686 0.88 EPHX2 (0.33) ALDH1A1EPHX2
SCHEMBL863208 0.88 EPHX2 (0.33) ALDH1A1EPHX2
SCHEMBL863289 0.88 EPHX2 (0.33) ALDH1A1EPHX2
SCHEMBL987158 0.88 EPHX2 (0.33) ALDH1A1EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3672601-B1 PROCESSES FOR PREPARING PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS VIA FAST-FLOW SYNTHESIS SAREPTA THERAPEUTICS INC (US) 2023-09-13 EP disclosed
US-11732008-B2 Preparation of functional homocysteine residues in polypeptides and peptides THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-08-22 US disclosed
US-20230193067-A1 METAL OXIDE COMPOSITION, LIGHT-EMITTING DEVICE USING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE LIGHT-EMITTING DEVICE SAMSUNG DISPLAY CO., LTD. (KR) 2023-06-22 US disclosed
US-11667652-B2 MCL1 inhibitors GILEAD SCIENCES, INC. (US) 2023-06-06 US disclosed
CN-108690045-B Diarylethene compounds and uses thereof 首诺加拿大公司 2022-08-30 CN disclosed
CN-113304729-B Mixture containing polyethylene glycol derivatives and application thereof 苏州工业园区森耀环保科技有限公司 2021-10-19 CN disclosed
WO-2021195599-A1 MTORC1 MODULATORS AND USES THEREOF AEOVIAN PHARMACEUTICALS, INC. (US) 2021-09-30 WO disclosed
CN-113304729-A Mixture containing polyethylene glycol derivatives and application thereof 苏州工业园区森耀环保科技有限公司 2021-08-27 CN disclosed
WO-2019060862-A1 PROCESSES FOR PREPARING PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS VIA FAST-FLOW SYNTHESIS SAREPTA THERAPEUTICS, INC. (US) 2019-03-28 WO disclosed
US-20180210240-A1 OPTICAL FILTER WITH LIGHT SOURCE SWITCH MATERIALS, INC. (CA) 2018-07-26 US disclosed
US-20130011751-A1 METAL OXYGEN BATTERY HONDA MOTOR CO., LTD. (JP) 2013-01-10 US disclosed
US-20120270934-A1 PROSTACYCLIN DERIVATIVES CONCERT PHARMACEUTICALS, INC. 2012-10-25 US disclosed
US-8093349-B2 Terminally modified polybranched polyimide, metal-plated terminally modified polybranched polyimide, and method for producing the same UBE INDUSTRIES, LTD. (JP) 2012-01-10 US disclosed
US-20100009206-A1 TERMINALLY MODIFIED POLYBRANCHED POLYIMIDE, METAL-PLATED TERMINALLY MODIFIED POLYBRANCHED POLYIMIDE, AND METHOD FOR PRODUCING THE SAME UBE INDUSTRIES, LTD. (JP) 2010-01-14 US disclosed
US-6929856-B2 Dicing tape UBE INDUSTRIES, LTD. (JP) 2005-08-16 US disclosed
US-6872457-B2 Atomic oxygen-resistant film UBE INDUSTRIES, LTD. (JP) 2005-03-29 US disclosed
US-20040023043-A1 Dicing tape UBE INDUSTRIES, LTD., A JAPANESE CORPORATION (JP) 2004-02-05 US disclosed
US-6686106-B2 POLYIMIDESILOXANE COPOLYMERS UBE INDUSTRIES, LTD. (JP) 2004-02-03 US disclosed
US-20030026998-A1 Atomic oxygen-resistant film UBE INDUSTRIES, LTD. (JP) 2003-02-06 US disclosed
US-20020001763-A1 Photosensitive resin compositions, insulating films, and processes for formation of the films UBE INDUSTRIES, LTD. 2002-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11732008-B2 Preparation of functional homocysteine residues in polypeptides and peptides BHMT2, BHMT, PTMS CA2 3667/4885PIK3CD 3984/4885ALDH1A1 4389/4885
US-20120270934-A1 PROSTACYCLIN DERIVATIVES PTGIS, PTGIR, PTGER1 CA2 526/4885PIK3CD 1110/4885ALDH1A1 1386/4885
US-11667652-B2 MCL1 inhibitors MCL1, BCL2L1, BCLAF1 CA2 4494/4885PIK3CD 864/4885ALDH1A1 946/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.